共 7 条
- [1] Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro StudyMOLECULES, 2023, 28 (07):Todsaporn, DuangjaiZubenko, AlexanderKartsev, VictorAiebchun, ThitinanMahalapbutr, PanupongPetrou, AnthiGeronikaki, AthinaDivaeva, LiudmilaChekrisheva, VictoriaYildiz, IlkayChoowongkomon, KiattaweeRungrotmongkol, Thanyada
- [2] Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRJOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (07) : 3002 - 3019Planken, SimonBehenna, Douglas C.Nair, Sajiv K.Johnson, Theodore O.Nagata, AsakoAlmaden, ChauBailey, SimonBallard, T. EricBernier, LouiseCheng, HengmiaoCho-Schultz, SujinDalvie, DeepakDeal, Judith G.Dinh, Dac M.Edwards, Martin P.Ferre, Rose AnnGajiwala, Ketan S.Hemkens, MichelleKania, Robert S.Kath, John C.Matthews, JeanMurray, Brion W.Niessen, SherryOrr, Suvi T. M.Pairish, MasonSach, Neal W.Shen, HongShi, ManliSolowiej, JamesKhanh TranTseng, ElaineVicini, PaoloWang, YuliWeinrich, Scott L.Zhou, RuZientek, MichaelLiu, LongqingLuo, YiqinXin, ShuiboZhang, ChengyiLafontaine, Jennifer
- [3] Discovery of a next generation irreversible inhibitor targeting the resistance mutation T790M and activating mutations in NSCLC with a broad selectivity margin over EGFR wild typeABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249Planken, SimonMurray, BrionLafontaine, JenniferWeinrich, ScottHemkens, MichelleKath, JohnNair, SajivJohnson, TheodoreCheng, HenrySutton, ScottZientek, MichaelYin, Min-JeanSolowiej, JimNagata, AsakoGajiwala, Ketan
- [4] Discovery and development of a series of irreversible EGFR_T790M 7H-pyrrolo[2,3-d]pyrimidine inhibitors with high selectivity over EGFR wild typeABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249Planken, SimonNair, SajivKath, JohnLafontaine, JenniferWeinrich, ScottCheng, HenrySutton, ScottJohnson, TheodoreZientek, MichaelNagata, AsakoGajiwala, KetanSolowiej, JimMurray, BrionYin, Min-JeanHemkens, Michelle
- [5] High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFRJOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11Wang, FangFu, ShaShao, QiongZhou, Yan-BinZhang, XiaoZhang, XuXue, CongLin, Jian-GuangHuang, Li-XiaZhang, LiZhang, Wei-MinShao, Jian-Yong
- [6] High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFRJournal of Translational Medicine, 11Fang WangSha FuQiong ShaoYan-Bin ZhouXiao ZhangXu ZhangCong XueJian-Guang LinLi-Xia HuangLi ZhangWei-Min ZhangJian-Yong Shao
- [7] Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBMCANCER RESEARCH, 2023, 83 (07)O'Connor, MatthewLucas, MatthewSmith, SherriTrombino, AnthonyEathiraj, SudharshanBuck, Elizabeth